Dual, DAC, & Novel: Do We Need More Targets or More Payloads?
3:40 pm - Thursday 26th February 2026
- Evaluating the value of payloads beyond Tubulin and Topoisomerases and why novel payload approaches will hold potential to overcome drug resistance
- What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success
- Specifically thinking about DACs, what is it about small molecule degraders that lend themselves to making good payloads?
- Discussing the panelists approach to business development. What would a win/win business deal look like that focuses on payloads?
